JKJoshua A. Kent

Joshua A. Kent

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joshua A. Kent has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Factors Influencing Stages of Mohs Micrographic Surgery: A Comprehensive Analysis

    by Elissa J. Goorman, Mehdi Boostani, Michael J. Bax, Cerrene N. Giordano, Li Yan, Joshua Kent, Lovely Pierre, Avery Williams, Wendy J. Huss, Kimberly L. Brady, et al.

    Background: Mohs micrographic surgery (MMS) achieves high cure rates for basal cell carcinoma (BCC) but may require multiple stages when tumors extend beyond clinically visible margins. Preoperative biopsy subtype information may help identify cases most likely to require additional stages and therefore benefit from adjunctive presurgical imaging. Methods: In this retrospective single‐center cohort of 1541 BCCs treated with MMS, we evaluated clinicopathologic features in relation to first‐stage positivity (defined as requiring two or more stages) and to the total number of Mohs stages, using univariate tests and multivariable logistic and negative binomial regression. Results: Four hundred tumors (26%) required two or more stages. First‐stage positivity was highest in infiltrative‐only tumors (40.7%) and lowest in nodular‐only tumors (21.1%). High‐risk BCCs with an infiltrative or micronodular component had higher first‐stage positivity (29.7%) than low‐risk tumors (22.5%). Larger tumors and H‐zone location also required more stages. After mutual adjustment, an infiltrative component (odds ratio [OR] 1.50, 95% confidence interval [95% CI] 1.11–2.03), tumor diameter (OR 1.23 per cm, 1.05–1.43) and H‐zone location (OR 1.95, 1.26–3.03) remained independently associated with first‐stage positivity. Conclusions: Biopsy‐reported histology, tumor size, and anatomic risk zone independently stratify the risk of additional MMS stages and can guide targeted preoperative imaging. Even “low‐risk” tumors with superficial components show notable first‐stage positivity. image

  • Cheek Merkel Cell Carcinoma Is Associated With Increased Nodal and Parotid Involvement

    by Joshua A. Kent, Kelvin Anderson, Christine R. Burton, Preethi Mozhiyil Chathoth, S. Lynn Sigurdson, William J. Magner, Gyorgy Paragh, Vishal Gupta

    Background: Merkel cell carcinoma ( MCC ) is a rare and highly aggressive neuroendocrine tumor that frequently arises in the head and neck region. While known risk factors include advanced age, Merkel cell polyomavirus infection, immunodeficiency, and ultraviolet exposure, the impact of anatomic subsite on disease behavior and prognosis remains poorly defined. Methods: We performed a retrospective cohort study of 46 patients with head and neck MCC treated by head and neck surgeons at Roswell Park Comprehensive Cancer Center between 2008 and 2022. Patients were identified using ICD ‐9 and ICD ‐10 codes. Clinical staging, pathologic findings, treatment modalities, recurrence rates, and survival outcomes were analyzed. Recurrence‐free survival and overall survival were evaluated using Kaplan–Meier analysis. Results: Among 46 patients with head and neck MCC , the cheek was the most common subsite (39.1%). Cheek MCC was associated with significantly higher rates of parotid involvement and lymph node metastasis compared with other subsites (69.2% vs. 25%, Fisher p = 0.03). In multivariable analysis adjusting for age and immunosuppression, cheek location was an independent predictor of nodal positivity (adjusted odds ratio [ OR] 7.4, 95% confidence interval [ CI] 1.4–41.0, p = 0.02). Among patients who recurred, cheek primaries tended to recur earlier (median 4 vs. 12 months), though this trend was not statistically significant. No statistically significant difference was observed in 3‐year overall or recurrence‐free survival across subsites on Kaplan–Meier analysis. Conclusions: Merkel cell carcinoma of the cheek is associated with increased parotid involvement, higher rates of nodal metastasis compared with other head and neck subsites, and cheek location was an independent predictor of nodal positivity. These findings suggest that anatomic subsite may influence disease behavior and highlight the need for larger studies to determine whether subsite‐specific management strategies are warranted. image

  • Open Access

    Liquid biopsy for molecular profiling in cutaneous T-cell lymphoma: a pilot feasibility study

    by Yoni Sacknovitz, Anna Sarah Erem, Joshua A. Kent, Maher Albitar, Tatyana Feldman, Barbara Pro, Seda S. Tolu, Alejandro A. Gru, Larisa Geskin

  • Cutaneous B-Cell lymphoma incidence trends in the United States: A surveillance, epidemiology, and end results analysis of 10,975 cases

    by Joshua A. Kent, Yoni Sacknovitz, Samuel A. Fisch, Sarah A. Erem, Barbara Pro, Seda S. Tolu, Alejandro Gru, Alfred I. Neugut, Larisa J. Geskin

  • Open Access

    Vohwinkel syndrome: Clinical and genetic insights from 26 years of follow-up

    by Yoni Sacknovitz, Celine M. Schreidah, Joshua A. Kent, Azriel Galbut, Aliza Wiederkehr, Ariella Rosenfeld, Todd H. Alter, Larisa J. Geskin

  • Open Access

    An Update on Single-Cell RNA Sequencing in Illuminating Disease Mechanisms of Cutaneous T-Cell Lymphoma

    by Sara Suhl, Alexander Kaminsky, Caroline Chen, Brigit A. Lapolla, Maggie H. Zhou, Joshua Kent, Abigail Marx, Ikenna David Nebo, Geat Ramush, Sophia Luyten, et al.

    Cutaneous T-cell Lymphomas (CTCLs) are a heterogeneous group of non-Hodgkin lymphomas that currently have an incompletely understood pathophysiology and several challenges in both diagnosis and management. Single-cell RNA sequencing (scRNA-seq) is a powerful tool that enables the analysis of gene expression at the individual-cell level, revealing cellular heterogeneity and a complex tumor microenvironment. As single-cell RNA sequencing has become increasingly utilized, we aimed to provide an update on recent notable applications of single-cell RNA sequencing in CTCL and their findings. The included studies highlight the intricate network of interactions in the tumor microenvironment that contributes to tumorigenesis. While CTCL is notoriously heterogeneous, our results identify key markers that prove promising for diagnosis, prognostication, and therapeutic targets.


  • Elucidating disparities in sunscreen coverage among state Medicaid preferred drug lists

    by Celine M. Schreidah, Joshua A. Kent, Oluwaseyi Adeuyan, Emily R. Gordon, Caroline Chen, Brigit A. Lapolla, Lauren M. Fahmy, Dawn Queen, Megan H. Trager, Faramarz H. Samie, et al.

    Regular application of over‐the‐counter (OTC) sunscreen is considered the foundation of skin cancer prevention, yet OTC sunscreen is not eligible for reimbursement in almost all state Medicaid benefit plans. On review of 111 Medicaid preferred drug lists (PDLs) across 50 states and the District of Columbia (DC), only five plans were identified that incorporate coverage of sunscreen. Thus, many recipients of Medicaid, the majority of whom are individuals and families of lower socioeconomic status, may encounter financial difficulty and thus forego utilizing sun protective measures due to financial constraints. Here, we compare current Medicaid coverage of OTC sunscreen and discuss calculated and theoretical annual costs of this skin cancer prevention method.